Congress Reconvenes in September to Advance Appropriations Bills, Looks Ahead to Possible Package of Health Policies

GLI looks forward to hitting Capitol Hill to support liver health policy priorities, including access to care, medical nutrition, early screening and diagnosis, and protection against policies that devalue patients living with disabling conditions and diseases.

CDC Leadership in Turmoil

The Trump administration has ousted CDC Director Susan Monarez just one month into her tenure, sparking the resignation of four senior officials in protest. Monarez, who reportedly resisted pressure to endorse sweeping changes to U.S. vaccine policy, has refused to step down, with her attorneys calling the move “legally deficient” and warning of the politicization of public health. In response, Senator Bill Cassidy (R-LA), chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, called for the U.S. Department of Health and Human Services Advisory Committee on Immunization Practices (ACIP) to indefinitely postpone their September 18th meeting. GLI will continue to monitor the situation and ensure opportunities for patient input remain available in relevant CDC processes and decisions.

Milestone for “Beyond the Biopsy” in MASH

The FDA has accepted a proposal to replace invasive procedures with noninvasive technologies in clinical trials for drugs targeting MASH — a critical step toward accelerating treatment development for millions living with this silent condition. Next, the FDA will initiate a Qualification Plan by collecting and analyzing all relevant data and then potentially issue a “QP Determination Letter” identifying other data necessary for the sponsor to collect before the submission of a full qualification package (FQP), which will be submitted to the FDA to make a determination. Still, this is an important first step. Thanks to the relentless advocacy of GLI’s Beyond the Biopsy program, the Liver Action Network, and patient advocates, meaningful progress is being made toward safer diagnosis and monitoring for people with MASH.

HHS Launches ‘MAHA in Action’ Tracker

The Department of Health and Human Services (HHS) launched a new platform that seeks to showcase federal initiatives and state-led reforms in U.S. food, health, and public safety systems. Explore the platform here.

RFK Jr. Warns Docs of Liability if They Stray From CDC on Vaccines

The American Academy of Pediatrics’ (AAP) recent pediatric COVID-19 vaccine recommendations, which differ from those of the CDC, have raised concerns from HHS Secretary Robert F. Kennedy Jr., who responded with an oblique warning to any physicians who might follow the AAP’s advice. “AAP should … be candid with doctors and hospitals that recommendations that diverge from the CDC’s official list are not shielded from liability under the 1986 Vaccine Injury Act,” Kennedy posted this week on X. The AAP recommendations, released on Tuesday, included a strong endorsement of COVID-19 shots for children ages 6 months to under 2 years. The group also recommended COVID-19 shots for older children if the parents wish to do so. Those recommendations differ from the guidance issued by the CDC, which has said the vaccines are not specifically recommended for children, although they can still get them if parents and providers agree.

HHS Terminates NIH Program Aimed at Diversifying Biomedical Workforce

The Department of Health and Human Services is terminating a National Institutes of Health grant program that supports students from marginalized backgrounds in the biomedical sciences. HHS Secretary Robert F. Kennedy Jr. announced the elimination of the program — the Minority Biomedical Research Support Program — in a document posted to the Federal Register on August 26. Kennedy cited the program’s failure to comply with the Trump administration’s executive orders that prevent federal agencies from supporting diversity, equity, and inclusion-related activities. Experts say that the termination of the program, which provided everything from funding for undergraduates’ lab salaries to mentorship from senior investigators, could close off scientific careers for individuals who wouldn’t otherwise have access to research opportunities.

Supreme Court Allows Trump to End DEI Research at NIH

NIH research grants that promote diversity, equity, and inclusion and what the Trump administration calls “gender ideology extremism” can now be terminated, following a Supreme Court decision. By a 5-4 vote, the justices lifted an order a federal court judge in Boston issued forcing the NIH to restore funding for more than 1,700 grants focused on heart disease, HIV/AIDS, Alzheimer’s disease, alcohol and substance abuse, and mental health issues. The administration had requested relief on the grounds that the federal government shouldn’t be required to pay for research — which it said amounted to $783 million in grants — not aligned with President Donald Trump’s executive orders and his administration’s priorities.

GLI Advocates for CMS to Advance Coverage of Treatments for Obesity

GLI recently urged CMS to include access for Medicare recipients to evidence-based obesity treatments such as intensive behavioral therapy (IBT) and Food & Drug Administration (FDA) – approved obesity medications in an upcoming proposed rule. Doing so will enable the Medicare program to align with the prevailing medical consensus that obesity is a chronic disease. To view the letter from GLI, the Obesity Care Action Network, please reach out to Alyssa Davenport at adavenport@globalliver.org.

Congress Positioned to Take Action on Enhanced Premium Tax Credits

If Congress also allows enhanced premium tax credits (which help people buy insurance coverage on the marketplace) to expire this year, more people could lose coverage, compounding the financial strain on already vulnerable providers. According to the Kaiser Family Foundation, the combined effects of the new budget law and the expiration of the ACA enhanced tax credits, compared to a scenario where the enhanced subsidies are in place, will result in the greatest increases in Louisiana, Florida, and Arizona, where the uninsured rate is expected to increase by at least 5 percentage points. In 34 states and the District of Columbia, the uninsured rates could be 3% or more higher than would otherwise be the case. GLI is following this issue closely as Congress reconvenes. The National Association of Insurance Commissioners (NAIC), bipartisan state insurance regulators from across the country, are again calling on Congress to extend the enhanced premium tax credits as soon as possible to protect subsidized and unsubsidized marketplace enrollees from large-scale premium increases should the subsidies expire. To read the letter to Congressional leaders, please reach out to Alyssa Davenport at adavenport@globalliver.org.

Senators Cassidy and Van Hollen Introduce the Cure Hepatitis C Act
GLI proudly supports legislation (S.1941) introduced by Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) aiming to implement a nationwide elimination program for the hepatitis C virus (HCV) in the United States. The bipartisan bill prioritizes patient health and safety, advances a national plan to eliminate hepatitis C, and seizes an opportunity to end a global health crisis through screening, diagnosis, and treatment. Since curative treatments became available over a decade ago, GLI has advocated for a national strategy to eliminate this now-treatable infectious disease. 

GLI’s statement can be found here. View AASLD’s action alert to help gather additional Senate co-sponsors. To view the letter of support, please reach out to Alyssa Davenport at adavenport@globalliver.org.

GLI Works With Congress to Protect and Advance Veterans’ Health

As part of GLI’s Beyond the Biopsy initiative, GLI and its partners sent a letter to the VA. GLI and AASLD also sent a follow-up letter to the VA calling for coverage consistent with clinical guidelines. Most recently, GLI sent letters to commercial payers whose policies restricted access to care based on flawed criteria, including Select Health of Utah, BCBS of Mississippi, Elevance Health (Anthem/CarelonRx), and Excellus BCBS. We are encouraged that several insurers have been responsive to GLI’s request for reconsideration.

We continue to encourage signatures here on a petition to all payers calling for coverage without biopsy for steatotic liver disease (SLD). GLI also urges advocates to contact their legislators to request the VA take steps to increase efforts to screen, diagnose, and treat veterans with MASH/NASH using non-invasive diagnostics and FDA-approved treatments, similar to Tricare, the Department of Defense’s (DoD) health program for active duty military members, their families, and retirees, and provide a briefing to the Committee on these efforts.

September Key for Congressional Appropriations Process 

Despite the White House’s preliminary fiscal year (FY) 2026 budget request outlining deep cuts to health and other non-defense discretionary programs, the Senate Appropriations Committee has advanced a bill funding the U.S. Department of Health and Human Services (known as the Labor/HHS bill) that is more generous than the President’s budget. Notably, funding levels for viral hepatitis at the CDC were not decreased in the Senate version. The Senate version also rejected proposed massive cuts to the NIH. GLI is encouraged that the report accompanying the Senate bill clearly articulates the importance of addressing liver-related challenges for health, such as:

• Deadliest cancers, liver (including cholangiocarcinoma);
• Vaccines for children, including hepatitis B;
• Biliary Tract Cancers;
• Liver Cancer;
• Co-infection of hepatitis B and HIV, with emphasis that liver disease is a leading cause of death for people living with HIV;
• Metabolic Dysfunction-Associated Steatotic Liver Disease [MASLD] Study;
• Vaccination and Screening for Hepatitis B;
• National Perinatal Hepatitis B Prevention Program, emphasizing preventing chronic liver disease and liver cancer;
• Strategic Plan for Trans-NIH Research to Cure Hepatitis B;
• Development of point-of-care tests for HBV, HDV, and the cancers caused by these viruses;
• Obesity as a disease, requiring comprehensive treatment.

GLI will continue to advocate for fully funded programs supporting liver health as Congress reconvenes in September. 

Additional Bills Benefiting Liver Patients

GLI is closely monitoring the reintroduction of legislation that helps patients access and afford the health care they need. We will continue to update this list. A few bills reintroduced so far include:

• Living Donor Protection Act (S.1552/H.R. 4583)
• Ensures living donors do not face discrimination from insurance companies, codifies Department of Labor (DOL) guidance that covers living donors under the Family Medical Leave Act (FMLA) in the private and civil service, removes barriers to organ donation, etc.
• Accelerating Kids’ Access to Care Act (S. 742/H.R.1509)
• Improves children’s access to needed out-of-state health care by streamlining the Medicaid provider screening and enrollment process.
• Medicare Multi-Cancer Early Detection and Screening Act (H.R.842/S.339) 
• Allows Medicare to cover simple blood tests to screen patients for cancer, leading to early diagnosis and treatment.
• HELP Copays Act (S.864)
• Requires health care insurers and pharmacy benefit managers (PBMs) to count payments they receive on a patient’s behalf, including payments from nonprofit organizations or drug manufacturers, toward the patient’s annual deductibles and out-of-pocket limit.
• Seniors’ Access to Critical Medications Act (H.R.2484)
• Allows Medicare patients to receive essential medications by mail or have caregivers and family members pick them up on their behalf. Reported favorably out of committee on April 29 in the House Energy and Commerce Committee.
• Pharmacy Benefit Manager (PBM) Transparency Act (S.526)
• Bans deceptive and unfair pricing schemes, prohibits arbitrary clawbacks of payments made to pharmacies and requires PBMs to report to the FTC on how much money they make through spread pricing and pharmacy fees.
• Capping Prescription Costs Act (S.529)
• Charlotte Woodward Organ Transplant Discrimination Prevention Act (H.R.1520/S.1782) 
• Passed the House. Take action to support Senate passage here!

Upcoming Events:

Congress Begins Work to Advance Appropriations Bills, Looks Ahead to Possible Package of Health Policies

GLI was pleased to see liver health priorities included in appropriations bills and intends to push Congress to take action on other pending health policy priorities.

GLI Works With Congress to Protect and Advance Veterans’ Health

As part of GLI’s Beyond the Biopsy initiative, GLI and its partners sent a letter to the VA. GLI and AASLD also sent a follow-up letter to the VA calling for coverage consistent with clinical guidelines. Most recently, GLI sent letters to commercial payers whose policies restricted access to care based on flawed criteria, including Select Health of Utah, BCBS of Mississippi, Elevance Health (Anthem/CarelonRx), and Excellus BCBS. 

We continue to encourage signatures here on a petition to all payers calling for coverage without biopsy for steatotic liver disease (SLD). GLI also urges advocates to contact their legislators to request the VA take steps to increase efforts to screen, diagnose, and treat veterans with MASH/NASH using non-invasive diagnostics and FDA-approved treatments, similar to Tricare, the Department of Defense’s (DoD) health program for active duty military members, their families, and retirees, and provide a briefing to the Committee on these efforts.

Congressional Appropriations Process Begins

Despite the White House’s preliminary fiscal year (FY) 2026 budget request outlining deep cuts to health and other non-defense discretionary programs, the Senate Appropriations Committee has advanced a bill funding the U.S. Department of Health and Human Services (known as the Labor/HHS bill) that is more generous than the President’s budget. Notably, funding levels for viral hepatitis at the CDC were not decreased in the Senate version. The Senate version also rejected proposed massive cuts to the NIH. GLI is encouraged that the report accompanying the Senate bill clearly articulates the importance of addressing liver-related challenges for health, such as:

• Deadliest cancers, liver (including cholangiocarcinoma);
• Vaccines for children, including hepatitis B;
• Biliary Tract Cancers;
• Liver Cancer;
• Co-infection of hepatitis B and HIV, with emphasis that liver disease is a leading cause of death for people living with HIV;
• Metabolic Dysfunction-Associated Steatotic Liver Disease [MASLD] Study;
• Vaccination and Screening for Hepatitis B;
• National Perinatal Hepatitis B Prevention Program, emphasizing preventing chronic liver disease and liver cancer;
• Strategic Plan for Trans-NIH Research to Cure Hepatitis B;
• Development of point-of-care tests for HBV, HDV, and the cancers caused by these viruses;
• Obesity as a disease, requiring comprehensive treatment.

GLI will closely follow the House process when Congress reconvenes in September. 

GLI is Deeply Concerned About Patient Access to Care, Particularly in Rural Hospitals

The reconciliation bill, H.R.1, included deep Medicaid cuts that are expected to reduce federal funding for rural areas by about $137 billion. These cuts will look different from state to state (KFF analysis), but the overall impact will likely include fewer people with health insurance coverage and severe financial strain on rural hospitals that already operate on thin margins. As rural hospitals make up at least a third of all hospitals in most states, this impact will be widespread. When these hospitals lose funding but are still expected to treat patients — especially those without insurance — they may be forced to lay off staff, cut services, delay facility upgrades, or, in some cases, shut down entirely.

To help offset these impacts, lawmakers created a $50 billion Rural Health Fund — a fraction of what rural areas are projected to lose. Only half the fund will be distributed across states with approved applications, and the rest will be awarded through an undetermined process. Notably, in conversations with stakeholders, CMS Administrator, Dr. Oz, has indicated that the Rural Health Fund should be used to make long-term investments in technologies to improve efficiency and address issues with cybersecurity, rather than being used to stopgap funding cuts. Adding to the challenge, the fund is temporary, while many of the Medicaid cuts are permanent.

 Another source of concern is the possible expiration of the Medicare-Dependent Hospital (MDH) program, through which Medicare provides additional payments to small rural hospitals that treat a high share of Medicare patients. These payments are set to end on September 30, 2025, unless Congress acts. Last week, CMS warned that if the program is not extended, rural hospitals could lose an additional $500 million in 2026 alone. More than half of MDH-designated hospitals already had negative margins in 2023, and losing this support could push many over the edge. 

GLI is very concerned that the combined effects of the Medicaid cuts, the uncertain rollout of the Rural Health Fund, and the looming expiration of the MDH program could be devastating for rural hospitals and for the patients they serve. Patients may find it harder to access care close to home, with fewer services, longer travel times, or even no local hospital at all. If Congress also allows enhanced premium tax credits (which help people buy insurance coverage on the marketplace) to expire, even more people could lose coverage, compounding the financial strain on these already vulnerable providers. Therefore, GLI will advocate for Congress and the administration to do everything in their power to address the challenges facing rural hospitals and the patients they serve.

U.S. HHS Pulls $500M in Funding for Vaccine Development

On August 5, the U.S. Department of Health and Human Services announced it would cancel contracts and pull funding for 22 projects investigating mRNA vaccines to fight respiratory viruses. This follows several decisions from the department and Secretary Robert F. Kennedy, Jr. that have undermined trust in vaccines – a key tool in the prevention of viral hepatitis B and D and liver cancer. GLI will continue to monitor the situation and advocate for lifesaving and essential immunizations to protect liver health and especially for our patients who are often immunocompromised.

Senators Cassidy and Van Hollen Introduce the Cure Hepatitis C Act
GLI proudly supports legislation (S.1941) introduced by Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) aiming to implement a nationwide elimination program for the hepatitis C virus (HCV) in the United States. The bipartisan bill prioritizes patient health and safety, advances a national plan to eliminate hepatitis C, and seizes an opportunity to end a global health crisis through screening, diagnosis, and treatment. Since curative treatments became available over a decade ago, GLI has advocated for a national strategy to eliminate this now-treatable infectious disease. We look forward to working closely with Congress and the current administration to get it over the finish line. 

GLI’s statement can be found here. View AASLD’s action alert to help gather additional Senate co-sponsors.

The House and Senate Reintroduce TROA, Administration Reported to Be Considering a Plan for Coverage

GLI applauds the reintroduction of the bipartisan Treat and Reduce Obesity Act (S.1973/H.R.4231), most recently reintroduced in the House with 12 original sponsors (15 total) on the heels of Senate reintroduction by Senators Bill Cassidy (R-LA) and Ben Ray Luján (D-NM). Within both the political and scientific realms, there is growing recognition of obesity as a chronic disease and the need to address and treat obesity like any other chronic disease. A robust body of research demonstrates the connection between obesity and serious liver diseases, such as metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), making access to treatment a top priority for GLI and patients. This bipartisan legislation would expand coverage of new health care specialists and chronic weight management medications for Medicare recipients. It will also work to mitigate the obesity epidemic by providing regular screenings. GLI’s most recent statement can be found here.

Additionally, the Washington Post recently reported that the administration is working on “an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.” GLI will continue to advocate for the administration to take steps to advance coverage of comprehensive obesity care, including medication. The supportive response to the Washington Post article from the Obesity Care Action Network, of which GLI is a member, can be found here.

Senate Help Discusses PBMs In The Context Of Health Care Affordability

On July 31, the Senate Health, Education, Labor, and Pensions (HELP) Committee held a hearing (TRP summary) entitled “Making Health Care Affordable: Solutions to Lower Costs and Empower Patients.” Members questioned the role of pharmacy benefit managers (PBM) in increasing health care costs, stirring bipartisan support for increasing transparency throughout the health care system. Additionally, the discussion highlighted the multifaceted nature of the nation’s health care system, and Members stressed the need to analyze all actors when considering reform efforts.

Policy Lessons from The Lancet Commission on Liver Cancer

The Lancet recently released a comprehensive commission on hepatocellular carcinoma (HCC), the most common form of liver cancer, highlighting that more than 60% of cases of liver cancer are preventable and that annual new cases are expected to double between 2022 to 2050. The Commission recommended that a sustained reduction of age-standardized incidence rate of 2-5% could prevent this trajectory. The report emphasized the role of policy and legislative changes to reduce the burden of liver cancer that align with GLI’s ongoing priorities:

• Access to liver cancer screening
• Focus on prevention, including vaccination for viral hepatitis and policy measures that reduce consumption of alcohol and unhealthy foods
• Investment in awareness campaigns about liver health

Read more from The New York Times (gift link).

Additional Bills Benefiting Liver Patients

GLI is closely monitoring the reintroduction of legislation that helps patients access and afford the health care they need. We will continue to update this list. A few bills reintroduced so far include:

• Living Donor Protection Act (S.1552/H.R. 4583)
  • Ensures living donors do not face discrimination from insurance companies, codifies Department of Labor (DOL) guidance that covers living donors under the Family Medical Leave Act (FMLA) in the private and civil service, removes barriers to organ donation, etc.
• Accelerating Kids’ Access to Care Act (S. 742/H.R.1509)
  • Improves children’s access to needed out-of-state health care by streamlining the Medicaid provider screening and enrollment process.
• Medicare Multi-Cancer Early Detection and Screening Act (H.R.842/S.339) 
  • Allows Medicare to cover simple blood tests to screen patients for cancer, leading to early diagnosis and treatment.
• HELP Copays Act (S.864)
  • Requires health care insurers and pharmacy benefit managers (PBMs) to count payments they receive on a patient’s behalf, including payments from nonprofit organizations or drug manufacturers, toward the patient’s annual deductibles and out-of-pocket limit.
• Seniors’ Access to Critical Medications Act (H.R.2484)
  • Allows Medicare patients to receive essential medications by mail or have caregivers and family members pick them up on their behalf. Reported favorably out of committee on April 29 in the House Energy and Commerce Committee.
• Pharmacy Benefit Manager (PBM) Transparency Act (S.526)
  • Bans deceptive and unfair pricing schemes, prohibits arbitrary clawbacks of payments made to pharmacies and requires PBMs to report to the FTC on how much money they make through spread pricing and pharmacy fees.
• Capping Prescription Costs Act (S.529)
• Charlotte Woodward Organ Transplant Discrimination Prevention Act (H.R.1520/S.1782)
  • Passed the House. Take action to support Senate passage here!

Upcoming Events: